Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Analyst Ratings

Where Fidelis Insurance Hldgs Stands With Analysts

By Benzinga Insights

October 6, 4:00 PM

Over the past 3 months, 11 analysts have published their opinion on Fidelis Insurance Hldgs (NYSE:FIHL) stock. These…

FIHL

Tesla Boosts Wages For German Factory Workers Amid Union Pressures

By Benzinga Neuro

November 6, 12:26 AM

Tesla has been facing pressure from Germany's influential IG Metall union, which seeks to unionize the plant and have Tesla agree to a union contract.

TSLA

Apple Ends Consulting Agreement With Jony Ive, Its Former Design Leader

By Charles Gross

July 13, 5:40 AM

-NY Times https://www.nytimes.com/2022/07/12/technology/apple-jony-ive-end-agreement.html

AAPL

Asia And Europe Markets Advance; Gold Inches Toward $2,400 Again – Global Markets Today While US Slept

By Akanksha Bakshi

May 10, 6:29 AM

On Thursday, May 9, U.S. stock markets closed higher. The Dow Jones Industrial Average rose for the seventh…

ADIV

Chardan Capital Downgrades Vascular Biogenics to Neutral

Related Posts

Where Fidelis Insurance Hldgs Stands With Analysts

Tesla Boosts Wages For German Factory Workers Amid Union Pressures

Apple Ends Consulting Agreement With Jony Ive, Its Former Design Leader

Asia And Europe Markets Advance; Gold Inches Toward $2,400 Again – Global Markets Today While US Slept